Minreksav (Cytisinicline)

Cytisinicline, the active ingredient in Minreksav, is a nicotinic acetylcholine receptor partial agonist presented as an oral formulation for oral use. It treats nicotine dependence and aids smoking cessation in adults. GNH USA supplies Minreksav as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Minreksav is a nicotinic receptor‑targeting agent used in the management of tobacco‑related disorders. - Smoking cessation: reduces cravings and withdrawal symptoms to help patients quit smoking. - Nicotine dependence: supports long‑term abstinence by moderating nicotine reward pathways. - Tobacco use disorder: assists in decreasing daily tobacco consumption and preventing relapse.

Cytisinicline may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Headache: intermittent tension‑type pain. - Insomnia: difficulty falling or staying asleep. - Vivid dreams: unusually intense or memorable dreams. - Dizziness: light‑headed sensation, especially on standing. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with rash, swelling, or breathing difficulty. - Mood changes: depression, anxiety, or irritability. - Chest pain: unexplained thoracic discomfort. - Cardiac arrhythmia: irregular heart rhythm. - Seizures: convulsive episodes. - Severe hypotension: marked drop in blood pressure.

Before initiating Minreksav, several safety considerations should be reviewed. - Cardiovascular assessment: evaluate patients with recent heart disease or uncontrolled hypertension. - Psychiatric monitoring: watch for new or worsening mood disorders. - Liver function: use caution in moderate to severe hepatic impairment. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Concomitant nicotine products: avoid using other nicotine replacement therapies simultaneously. - Store at room temperature: keep in the original container, protect from moisture and light.

Cytisinicline can interact with several medication classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may precipitate hypertensive crisis. - Strong CYP2D6 inhibitors: can increase Cytisinicline plasma concentrations. - Other nicotine replacement therapies: additive nicotine effect may increase toxicity.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may exacerbate insomnia. - Antihypertensive agents: possible attenuation of blood‑pressure control. - Alcohol: may enhance central nervous system depression.